Iterative Health vs Triomics (2026)
Two companies between clinical care and clinical research, reached from opposite directions. Iterative Health started with SKOUT, an FDA cleared polyp detection device for colonoscopy, and now presents itself mainly as a company accelerating clinical research through its network. Triomics started with the chart: oncology tuned models that screen patients against open trials, prepare visit summaries and abstract registry data, citing the chart line behind every answer. For a gastroenterology unit wanting detection, weigh how far Iterative's attention has moved to research. For a cancer center wanting more patients into trials, Triomics does the eligibility reasoning and Iterative brings a network.
- SKOUT, 510(k) cleared in 2022, with a randomized trial in Gastroenterology reporting a 27 percent relative increase in adenomas detected.
- A clinical research network that is now the larger part of what the company offers.
- Gastroenterology as the home specialty, for a unit weighing detection and trial participation together.
- Oncology tuned chart reading with published validation in npj Digital Medicine, citing the line behind every answer.
- Daily screening of every scheduled patient against open trials, delivered as a cited worklist for coordinators.
- Delivered inside Epic, OncoEMR and iKnowMed, with registry abstraction alongside.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Iterative Health and Triomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Iterative Health | Triomics |
|---|---|---|
| Primary category | Radiology & Imaging AI | Clinical Trials AI |
| Founded | Not recorded | 2021 |
| Headquarters | Cambridge, Massachusetts | New York, New York, United States |
| Website | iterative.health | triomics.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Iterative Health, legally Iterative Scopes, Inc., is based in Cambridge, Massachusetts and runs two businesses under one name: a cleared AI device for colonoscopy and a clinical research site network. Its website leads with the research network, and the device is one of three solutions listed in the footer.
Source: AI Health Index, September 2026
Oncology AI that reads the whole patient chart. OncoLLM, a family of oncology-tuned models tuned further on each institution's records, reads every note, report, scan and fax and returns structured answers with a citation to the line in the chart behind each one.
Source: AI Health Index, September 2026
Questions buyers ask
How do Iterative Health and Triomics handle patient data?
For Iterative Health, the company's privacy policy, updated 1 September 2026, covers personal information from business customers and website visitors, says information is kept as long as necessary to provide the services and protected by industry standard measures, and lists categories of service providers, including platform hosting and security monitoring, without naming them.
With Triomics, the company says its models are tuned on each institution's own records with human feedback and deployed as a customized model per partner, and Symphony learns each physician's note style; the privacy page points to a General Privacy Policy on HIPAA. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Iterative Health and Triomics?
In Iterative Health's case, the K213686 clearance summary reports 1,359 patients in the modified intention to treat population, 682 colonoscopies with SKOUT and 677 without, no adverse events or complications, and, as a second primary endpoint, positive percent agreement of 70.9 percent with the device against 75.7 percent without.
For Triomics, the PRISM trial-matching system was published in npj Digital Medicine (October 2024), reporting 95 percent accuracy in matching patients to trials against expert review. An ASCO 2025 abstract co-authored with a leading academic medical center reports enterprise screening with OncoLLM producing 40 percent more trial matches and a 30 percent lift in trial accruals. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do Iterative Health and Triomics leave to the clinician?
With Iterative Health, the K213686 indication is a computer aided detection tool that gives polyp location information to assist trained gastroenterologists during colonoscopy in adults having screening or surveillance, for white light colonoscopy only.
In Triomics' case, each value carries a citation that opens the source line in the chart, and audit trails are native. The company describes this as 'cited, auditable, never a black box', a claim about the basis of each output that the citations back up. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Iterative Health's site now leads with research, with the device in a footer link, which changes what a purchaser is committing to and how the device is likely to be supported. Iterative publishes neither business associate terms nor a security attestation.
Triomics reports finding 90 percent of eligible patients and publishes a trust center.